The FDA has released three new guidance documents on cell and gene therapy development, covering clinical trial design and ...

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...

Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) ...

BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.

Award will support development of a single dose in vivo chimeric antigen receptor T cell (CAR-T) therapy to retrain immune cells directly within ...

SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors ...

– Initial translational results support proof-of-mechanism with immune reprogramming resulting in tumor penetration and pro-inflammatory alteration in the TME – CAMBRIDGE, Mass., May 30, 2025 ...